- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00465400
Oxidative Stress in Patients With Age-Related Macular Degeneration
Quantification of Oxidative Stress in Patients With Age-Related Macular Degeneration Prior to and After Photodynamic Therapy: a Comet Assay Analysis
First, to quantify, by means of comet assay analysis, systemic oxidative stress in patients with non-exudative and exudative age-related macular degeneration (AMD) and compare results to healthy controls.
Second, to quantify systemic oxidative stress in patients with exudative AMD prior to and after photodynamic (PDT) therapy.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Oxidative stress is the major factor that plays a role in the pathogenesis of age-related macular degeneration (AMD), which is a leading cause of blind registration in the developed world. The term oxidative stress refers to reversible damage to molecules, such as for example DNA, by reactive forms of oxygen (eg. free oxygen radicals). This damage is repaired is normally repaired in our body.
AMD is classified in two forms: the dry (non-exudative) and wet (exudative) form. The exudative form of AMD occurs when new blood vessels form to improve the blood supply to retinal tissue. However, the new blood vessels are very delicate and break easily, causing bleeding and serious vision loss. The standardized method used to treat exudative AMD is photodynamic therapy (PDT). This treatment is based upon the infusion of a drug that can be activated by light and produces free radicals that destroy these newly formed vessels. In other words, these new vessels are destroyed by an iatrogenic source of oxidative stress. This means that the factor that originally caused the disease AMD, namely oxidative stress, is finally used as a form of treatment- to destroy these newly formed blood vessels.
In the present study we would like to quantify in a first step the level of systemic oxidative stress in patients with non-exudative and exudative AMD and compare to healthy controls. In a second step we would like to test whether the treatment (PDT) for patients with exudative AMD additionally increases systemic oxidative stress. Oxidative stress is quantified in our laboratory by means of single cell gel electrophoresis or comet assay.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
BS
-
Basel, BS, Suisse, 4031
- University Eye Clinic Basel
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
For patients with dry non- exudative AMD:
- Patients between the ages of 50 and 85 yr inclusive.
- Study eye must have a diagnosis of nonexudative "dry" AMD with ≥10 large soft, semisoft, and/or confluent drusen within 3,000 nm of the foveal center.
- Study eye must have a best corrected visual acuity using the ETDRS chart between 0.1 patem and 0.8 patem inclusive.
- Geographic atrophy is allowed as long as it is less than 3 disc diameters within 3,000 nm of the foveal center.
- Study eye must not have conditions that limit the view of the fundus.
For patients with exudative AMD with clinical indication for PDT treatment:
- Patients between the ages of 50 and 85 yrs with exudative AMD with clinical indication for PDT treatment.
- Primary or recurrent subfoveal CNV due to AMD
- Central 1-mm retinal thickness (optical coherence tomography) > 300 um
- Best-corrected visual acuity, using ETDRS charts, of > 0.05patem
- Evidence of recent disease progression, including the loss of at least 1 line of visual acuity or macular hemorrhage within the previous 12 wks.
For healthy subjects:
- An intraocular pressure < 20 mmHg
- Normal blood pressure (100-140/60-90mm Hg)
- Best corrected visual acuity, using EDTRS charts of above 0.6 patem in both eyes
- No pathological findings upon slit-lamp examination and indirect fundoscopy
Exclusion Criteria:
- History of other ocular or systemic disease
- History of chronic or current systemic or topical medication, or of significant drug or alcohol abuse(significant is defined as that which may influence results of the study
- History of ocular trauma or intraocular surgery within the past 6 months
- History of infection or inflammation within the past 3 months
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Selim Orgül, MD, University Eye Clinic Basel
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 086-Mom-2006-004
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Dégénérescence maculaire
-
Innovative MedicalComplétéÉpaississement de la maculaÉtats-Unis
-
The University of QueenslandRetiré
-
Osias Francisco de SouzaInconnueDégénérescence de la macula et du pôle postérieurBrésil
-
Manhattan Eye, Ear & Throat HospitalNorthwell HealthRetiréDystrophie Patronale de la MaculaÉtats-Unis
-
Benha UniversityRecrutementDégénérescence de la macula jauneEmirats Arabes Unis
-
The Filatov Institute of Eye Diseases and Tissue...Odessa National Medical University; Mykolaiv Region Ophthalmogical Hospital; Central Polyclinic of Internal Affairs of UkraineInconnueStries angioïdes de la maculaUkraine
-
Central Hospital, Nancy, FranceInconnue
-
Hanyang UniversityComplétéAnomalie de la maculaCorée, République de
-
National Taiwan University HospitalInconnue
-
Brighton and Sussex University Hospitals NHS TrustComplétéDégénérescence maculaire liée à l'âge | Cataracte Sénile | Membrane épirétinienne | Traction vitréomaculaire | Trou de la maculaRoyaume-Uni